Recognizing the challenges of enhancing the availability of novel antimicrobials, the Public Health Agency of Canada asked the CCA to examine economic pull incentives for encouraging market entry and sustained market availability of high-value antimicrobials in Canada. [...] To the contrary, the availability of a new antibiotic comes at the end of a risky and laborious process that begins with lab-based scientific enquiry and culminates in expensive, challenging human trials to demonstrate the effectiveness and safety of the new medication. [...] The role of the peer review monitor is to ensure that the Panel gives full and fair consideration to the submissions of the peer reviewers. [...] Council of Canadian Academies | xv Acknowledgments The Panel and CCA staff would like to express their sincere appreciation to the following individuals: Jenny Hellman, Project Leader, Public Health Agency of Sweden; Dagmar Reitenbach, Lead, Global Health Policy, Ministry of Health, Government of Germany, and Céline Pulcini, Chief of Mission for the Prevention of Antimicrobial Resistance and Coord. [...] Recognizing the urgency of this issue, the Public Health Agency of Canada (PHAC) asked the CCA to convene an expert panel to provide an evidence-based, authoritative assessment that answers the following question: What economic pull incentives have the greatest potential for success in encouraging the market entry and sustained market availability of high-value antimicrobials for use in humans in.
- Pages
- 144
- Published in
- Canada
